Persistent Hypoxia After Tricuspid Valve Replacement Authors: John Nguyen, Thomas Merino, Vijay Kandula, Leticia Castillo Kontak, Raul Mercado Garcia, Angel Caldera, Aditi Shankar, Rafael Gonzalez, Soumya Neravetla, Jose F Condado Published: 2026 ABSTRACT AbstractBackgroundTranscatheter tricuspid valve replacement (TTVR) is a novel therapy for symptomatic severe tricuspid regurgitation in high-risk surgical patients. Platypnea-orthopnea syndrome has not previously been described as a complication of TTVR.Case SummaryA 76-year-old woman with symptomatic severe tricuspid regurgitation underwent successful TTVR but developed persistent hypoxia despite negative pulmonary work-up. Her hypoxia followed a platypnea-orthodeoxia pattern. Echocardiography revealed a patent foramen ovale (PFO) with right-to-left shunting. She then underwent successful percutaneous PFO closure, with resolution of her hypoxia.DiscussionAcute post-TTVR anatomic and hemodynamic changes can include right atrial distortion and right ventricular dysfunction in the absence of pulmonary hypertension. These changes may acutely worsen right-sided pressures, leading to right-to-left shunting through an existing PFO.Take-Home MessagesPersistent hypoxia with a platypnea-orthodeoxia pattern immediately after TTVR should prompt thorough work-up including evaluation for PFO. Percutaneous PFO closure can address platypnea-orthodeoxia syndrome in this setting.Key words: anatomic distortion, interatrial communication, PFO, percutaneous device closure, platypnea-orthodeoxia syndrome, shunting, TTVR, TR History of Presentation A 76-year-old woman with severe symptomatic tricuspid regurgitation (TR), deemed at high risk for surgical therapy by the multidisciplinary heart team and not amenable for edge-to-edge repair given a large coaptation gap, underwent transcatheter tricuspid valve replacement (TTVR), with reduction of TR to trivial. After the procedure, she was hemodynamically stable but developed persistent hypoxia that worsened in the upright position, requiring high-flow oxygen by nasal cannula. The patient did not require any supplemental oxygen when seated or lying down. Past Medical History The patient's medical history included hypertension, hyperlipidemia, atrial fibrillation, patent foramen ovale (PFO), heart failure with preserved ejection fraction, severe TR, and worsening exertional dyspnea. Differential Diagnosis The differential diagnoses considered in her case included pneumonia, lung injury, pulmonary embolism, congestive heart failure, and right-to-left shunt. Investigations •Laboratory tests: B-type natriuretic peptide of 154 pg/mL (reference: 0-100 pg/mL). Laboratory tests: B-type natriuretic peptide of 154 pg/mL (reference: 0-100 pg/mL). •Chest x-ray: No acute cardiopulmonary pathology. Chest x-ray: No acute cardiopulmonary pathology. •Lower extremity venous duplex: Deep vein thrombosis in bilateral profunda femoral and popliteal veins. Lower extremity venous duplex: Deep vein thrombosis in bilateral profunda femoral and popliteal veins. •Chest computed tomography angiography: Enlargement of the right and left main pulmonary arteries, no filling defect to suggest pulmonary emboli. Chest computed tomography angiography: Enlargement of the right and left main pulmonary arteries, no filling defect to suggest pulmonary emboli. •Transthoracic echocardiography (TTE): Biatrial dilation, normal left ventricular size/systolic function (ejection fraction: 65%-70%), right ventricle (RV) severely dilated and hypocontractile (new), well-seated 52-mm Evoque TTVR, color Doppler showing interatrial flow (Figure 1), saline contrast study early positive for interatrial shunt with quiet respiration and Valsalva maneuver (Figure 2). Transthoracic echocardiography (TTE): Biatrial dilation, normal left ventricular size/systolic function (ejection fraction: 65%-70%), right ventricle (RV) severely dilated and hypocontractile (new), well-seated 52-mm Evoque TTVR, color Doppler showing interatrial flow (Figure 1), saline contrast study early positive for interatrial shunt with quiet respiration and Valsalva maneuver (Figure 2). •Transesophageal echocardiography (TEE): Saline contrast study positive for interatrial shunt with Valsalva maneuver and quiet respiration, consistent with prior PFO (Figure 3); grade IV shunt with immediate passage of saline contrast (Figure 4, Figure 5, Figure 6); 52-mm Evoque TTVR with no prosthetic tricuspid stenosis and mild regurgitation, mean gradient 1 mm Hg at a heart rate of 46 beats/min. Transesophageal echocardiography (TEE): Saline contrast study positive for interatrial shunt with Valsalva maneuver and quiet respiration, consistent with prior PFO (Figure 3); grade IV shunt with immediate passage of saline contrast (Figure 4, Figure 5, Figure 6); 52-mm Evoque TTVR with no prosthetic tricuspid stenosis and mild regurgitation, mean gradient 1 mm Hg at a heart rate of 46 beats/min. TTE After Noted Platypnea-Orthodeoxia, Subcostal View With Color Doppler Showing Interatrial Flow (Red Arrow) LA = left atrium; RA = right atrium; TTE = transthoracic echocardiography. TTE After Noted Platypnea-Orthodeoxia, Apical 4-Chamber View With Bubble Study Positive for Interatrial Shunt (Left Atrial Agitated Saline Contrast Within 3 Cardiac Cycles) With Quiet Respiration and Valsalva LA = left atrium; RA = right atrium; TTE = transthoracic echocardiography. Pre-TTVR Screening TEE Midesophageal Bicaval View Showing PFO (Red Arrow) LA = left atrium; PFO = patent foramen ovale; RA = right atrium; TEE = transesophageal echocardiography; TTVR = transcatheter tricuspid valve replacement. Intraoperative TEE During TTVR, Midesophageal Bicaval View Again Showing PFO (Red Arrow) Abbreviations as in Figure 3. Intraoperative TEE During TTVR, Midesophageal Short-Axis View Color Compare Showing PFO (Red Arrow) and Right-to-left Shunt on Color Doppler (Blue Arrow) Abbreviations as in Figure 3. Intraoperative TEE During TTVR, Midesophageal Short-Axis View With Bubble Study Showing PFO (Red Arrow) and Right-to-Left Shunting Within 3 Cardiac Cycles Abbreviations as in Figure 3. Management •Supplemental oxygen via nasal cannula (3 L/min). Supplemental oxygen via nasal cannula (3 L/min). •Anticoagulation with rivaroxaban. Anticoagulation with rivaroxaban. •Intravenous furosemide that was transitioned to oral torsemide. Intravenous furosemide that was transitioned to oral torsemide. •Heart team discussion given platypnea-orthopnea syndrome (POS) and suspicion of right-to-left intracardiac shunting via PFO. Heart team discussion given platypnea-orthopnea syndrome (POS) and suspicion of right-to-left intracardiac shunting via PFO. Interventions •PFO closure was pursued, with successful PFO closure device placement (Figure 7). Intraoperative TEE showed PFO closure device placement with minimal residual shunt (Figure 8). Repeat TTE showed no residual interatrial shunting (Figure 9). PFO closure was pursued, with successful PFO closure device placement (Figure 7). Intraoperative TEE showed PFO closure device placement with minimal residual shunt (Figure 8). Repeat TTE showed no residual interatrial shunting (Figure 9). PFO Closure Device Placement (Red Arrow) With TTVR Valve (Blue Arrow) and Coronary Sinus Pacemaker Leads Present (Yellow Arrow) PFO = patent foramen ovale; TTVR = transcatheter tricuspid valve replacement. Intraoperative TEE After PFO Closure Device Placement (Red Arrow), Midesophageal Short-Axis View With Minimal Residual Shunt LA = left atrium; PFO = patent foramen ovale; RA = right atrium; TEE = transesophageal echocardiography. Repeat TTE After PFO Closure Device Placement (Red Arrows), Subcostal View Showing No Residual Interatrial Shunting on Color Doppler TTE = transthoracic echocardiography; remaining abbreviations as in Figure 8. Outcome and Follow-Up •Postprocedure, patient oxygen saturation normalized without oxygen supplementation, and TTE showed no residual interatrial shunt. Postprocedure, patient oxygen saturation normalized without oxygen supplementation, and TTE showed no residual interatrial shunt. •The patient was started on antiplatelet therapy after PFO closure in addition to rivaroxaban. She was discharged on aspirin and rivaroxaban given concomitant lower extremity deep vein thrombosis requiring anticoagulation. The patient was started on antiplatelet therapy after PFO closure in addition to rivaroxaban. She was discharged on aspirin and rivaroxaban given concomitant lower extremity deep vein thrombosis requiring anticoagulation. •At follow-up, the patient remained asymptomatic, and TTE showed a well-seated interatrial septal occluder with no evidence of interatrial flow, and a well-seated Evoque TTVR with mild valvular TR. At follow-up, the patient remained asymptomatic, and TTE showed a well-seated interatrial septal occluder with no evidence of interatrial flow, and a well-seated Evoque TTVR with mild valvular TR. Discussion TTVR is a treatment option for patients with severe symptomatic TR, poor candidacy for surgery, and complex anatomy unsuitable tricuspid transcatheter edge-to-edge repair.1 These complexities include enlarged tricuspid annulus or coaptation gaps, excessive leaflet tethering, and pacemaker/defibrillator lead impingement.1 TTVR has been shown to reduce TR severity and improve quality of life up to 2 years of follow-up.1 Hemodynamic and echocardiographic improvements have also been shown, attributed to reverse RA dilation and reverse RV remodeling over time. However, periprocedural and immediate postprocedural complications can include atrioventricular conduction disease requiring permanent pacemaker implantation, excessive bleeding, and right heart dysfunction.1 To date, POS has not been described as a common adverse effect of TTVR. For this patient, the mechanism of disease likely involved acute post-TTVR RA anatomic distortion and new or unmasked RV dysfunction leading to transient increase of right-sided pressures, and thus, POS via a known PFO. There is at least 1 published case of POS from PFO after transcatheter aortic valve replacement, where computed tomography showed horizontal aorta compressing the RA.2 Immediately after TTVR, right-sided anatomical changes may promote increased right-to-left shunting in the setting of a pre-existing PFO.3 The prosthetic TTVR frame deployed in the tricuspid annulus may effectively elevate the annular plane. The reduction of regurgitant volume can also reduce RA and inferior vena cava stretching. Although RA reverse remodeling and dilation reduction can occur over time, postprocedural acute reduction in regurgitant volume and RA pressure may alter the RA shape and configuration of the atrial septal structures such as an existing PFO.3 In an upright posture, the inferior vena cava jet may become more coaxial to an existing PFO orifice, leading to greater right-to-left shunting. In our case, artifact created by the TTVR precluded direct comparison of the preprocedural and postprocedural echocardiographic images. The reduction of severe TR immediately after TTVR improves forward flow that subsequently can increase RV afterload. This can cause an increase in RV pressure that overwhelms an RV that has been remodeled by longstanding severe TR, leading to RV dysfunction and elevated RA pressure in the absence of pulmonary hypertension. With a concomitant PFO, the elevated RA pressure can surpass left atrial pressure, promoting flow from the RA into the left atrium. Acute post-TTVR RV dysfunction combined with the acute post-TTVR anatomical changes of the RA can lead to dynamic right-to-left shunting through an existing PFO, resulting in POS.4,5 Further quantification with repeating right heart catheterization may have helped to fully objectify this theory. However, our patient improved and was weaned off oxygen therapy after PFO closure. Interestingly, this patient had a known history of PFO but had no prior embolic event, and thus, did not have an indication for closure before TTVR.6 Undifferentiated hypoxia after TTVR should warrant thorough work-up to assess a wide differential diagnosis, including decompensated heart failure, pulmonary embolism, and pneumonia. Medical management should take place to address any periprocedural complications. With any platypnea-orthodeoxia, work-up to confirm PFO including TTE and TEE should be performed before PFO closure. PFO closure has been shown to effectively address POS as a stand-alone indication.5,7 This case describes a rare complication of POS in a novel TTVR treatment option. Conclusions TTVR is a treatment option in select patients with symptomatic severe TR and poor candidacy for surgery and transcatheter edge-to-edge repair. Acute post-TTVR anatomical and hemodynamic changes in the RA and RV may unmask or worsen any underlying intracardiac shunting. In the setting of an existing PFO, RA configurational changes and RV dysfunction may work in tandem to increase right-sided pressures without pulmonary hypertension, and worsen right-to-left shunting through a PFO, leading to platypnea-orthodeoxia syndrome. PFO should be highly considered on the differential diagnosis for any post-TTVR patient with persistent hypoxia, particularly if the hypoxia follows a paradoxical pattern with postural changes. Take-Home Messages •Acute post-TTVR changes include right atrial and right ventricular anatomic and hemodynamic changes that may promote right-to-left intracardiac shunting. Acute post-TTVR changes include right atrial and right ventricular anatomic and hemodynamic changes that may promote right-to-left intracardiac shunting. •Persistent hypoxia acutely after TTVR with a platypnea-orthodeoxia pattern and negative pulmonary work-up should prompt evaluation for patent foramen ovale. Persistent hypoxia acutely after TTVR with a platypnea-orthodeoxia pattern and negative pulmonary work-up should prompt evaluation for patent foramen ovale. Visual SummaryTimeline of the CaseTimeEventsDay 1 (admission)A 76-year-old woman with severe TR and NYHA functional class III symptoms, deemed at prohibitive surgical risk and with anatomy unsuitable for transcatheter edge-to-edge repair, underwent planned TTVR with reduction of TR to trivial.POD 1Had dyspnea and hypoxia requiring O2 nasal cannula. Chest x-ray showed mild pulmonary edema. Patient started on IV furosemide.POD 2Developed fever without any symptoms of infection. Continued O2 nasal cannula and IV furosemide.POD 3Lower extremity venous duplex showed bilateral DVT. Patient started on rivaroxaban.POD 6Occasional dyspnea and hypoxia treated with O2. Chest x-ray showed mild pulmonary vascular congestion. Patient started on oral torsemide.POD 8No dyspnea but hypoxic with exertion. Chest CTA showed no pulmonary embolism. TTE showed adequate TTVR function and Doppler flow consistent with known PFO.POD 14Continued to have hypoxia requiring O2 nasal cannula.POD 16Hypoxia noted to be minimal while sitting or lying, but immediately worsened with standing/ambulating. Suspicious for platypnea-orthodeoxia due to PFO.POD 18TTE with adequate TTVR function, Doppler flow and saline contrast study consistent with PFO. Heart team meeting with decision to proceed with TEE and PFO closure.POD 20TEE with appropriate TTVR function and saline contrast demonstrating PFO. Patient underwent PFO closure device placement.POD 21Hypoxia resolved. Supplemental O2 and torsemide were discontinued. Patient continued on aspirin and rivaraxaban.POD 22Patient discharged home without needing supplemental O2.15-day follow-upPatient clinically well with no sequelae. TTE showed adequate TTVR function and a well-seated PFO closure device with normal function.30-day follow-upPatient clinically well with no sequelae.CTA = computed tomography angiography; DVT = deep vein thrombosis; IV = intravenous; PFO = patent foramen ovale; POD = postoperative day; TEE = transesophageal echocardiography; TR = tricuspid regurgitation; TTE = transthoracic echocardiography; TTVR = transcatheter tricuspid valve replacement. Timeline of the Case CTA = computed tomography angiography; DVT = deep vein thrombosis; IV = intravenous; PFO = patent foramen ovale; POD = postoperative day; TEE = transesophageal echocardiography; TR = tricuspid regurgitation; TTE = transthoracic echocardiography; TTVR = transcatheter tricuspid valve replacement. Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose. Footnotes The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. References